Eesti - eesti - Ravimiamet

aramis pharma kft - rilusool - õhukese polümeerikattega tablett - 50mg 56tk

Eesti - eesti - Ravimiamet

patent pharma kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 30000rÜ 2tk; 30000rÜ 4tk; 30000rÜ 3tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan s.a.s. - pregabaliin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - epilepsypregabalin mylan pharma on näidustatud adjunctive ravi täiskasvanutel, osaline krambid koos või ilma sekundaarse üldistada. generaliseerunud Ärevus disorderpregabalin mylan pharma on näidustatud ravi generaliseerunud Ärevushäire (gad) täiskasvanutel.

Eesti - eesti - Ravimiamet

swixx biopharma kft. - paratsetamool+ibuprofeen - õhukese polümeerikattega tablett - 500mg+150mg 16tk; 500mg+150mg 32tk; 500mg+150mg 10tk; 500mg+150mg 8tk; 500mg+150mg 20tk

Eesti - eesti - Ravimiamet

strides pharma (cyprus) limited - alfakaltsidool - pehmekapsel - 1mcg 30tk; 1mcg 50tk; 1mcg 100tk; 1mcg 90tk

Eesti - eesti - Ravimiamet

strides pharma (cyprus) limited - alfakaltsidool - pehmekapsel - 0,25mcg 100tk; 0,25mcg 50tk; 0,25mcg 90tk

Eesti - eesti - Ravimiamet

strides pharma (cyprus) limited - alfakaltsidool - pehmekapsel - 0,5mcg 30tk; 0,5mcg 100tk; 0,5mcg 50tk; 0,5mcg 90tk

Eesti - eesti - Ravimiamet

swixx biopharma kft. - paratsetamool+ibuprofeen - suukaudne suspensioon - 32mg+9,6mg 1ml 200ml 1tk; 32mg+9,6mg 1ml 100ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

viatris limited - klopidogreel-besilaat - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmendi elevatsiooniga ägeda müokardi infarkti korral kombinatsioonis asa on meditsiiniliselt ravitud patsientide abikõlblikud trombolüütiline ravi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. täiendava teabe jaoks vt osa 5.